Antengene Biologics Limited
Clinical trials sponsored by Antengene Biologics Limited, explained in plain language.
Biopharmaceutical company developing innovative oncology and hematology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for stomach cancer: experimental drug combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug called ATG-022 combined with the immunotherapy pembrolizumab (Keytruda), with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and is HER2-negative. The trial aims to fin…
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC